• Idorsia signed an exclusive deal with Jamjoom Pharma to commercialize insomnia drug QUVIVIQ in Saudi Arabia, covering distribution across the Levant.
• Jamjoom will hold the Saudi marketing authorization, leading regulatory filings, promotion, distribution, sales across the covered territories.
• Idorsia will supply finished product, receiving an upfront payment, additional milestones, royalties on net sales.
• Agreement extends QUVIVIQ’s partnered footprint in the Middle East as Idorsia pursues broader international rollout of the drug.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Idorsia Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270100OMX_____CNEWS_EN_GNW1001244477_en) on July 27, 2026, and is solely responsible for the information contained therein.